PTC Therapeutics, Inc. (PTCT) Tuesday announced positive data from two different long-term extension studies of vatiquinone in Friedreich ataxia (FA). The primary endpoints of the studies were met. Following the news, the company's shares were trading more than 5 percent up in pre-market.
Friedreich ataxia (FA) is a rare, genetic disorder that causes progressive damage to the nervous system.
Results from the MOVE-FA long-term extension study showed that 144 weeks of vatiquinone treatment resulted in a 3.7-point benefit on the modified Friedreich Ataxia Rating Scale (mFARS). mFARS is a series of physical examination assessments to measure disease progression in patients with FA. PTC said this treatment difference on the primary endpoint represents a 50 percent slowing in disease progression over 3 years.
Additionally, PTC analyzed long-term open-label data from an earlier study of vatiquinone in adults with FA. Following 24-months of treatment with vatiquinone, subjects had a 4.8-point benefit on the mFARS.
The company plans to submit NDA for vatiquinone in December this year.
PTC shares had closed at $34.99, down 0.31 percent on Monday. It has traded in the range of $17.53 - $40.69 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.